These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21838683)

  • 1. Current trends in β-lactam based β-lactamases inhibitors.
    Biondi S; Long S; Panunzio M; Qin WL
    Curr Med Chem; 2011; 18(27):4223-36. PubMed ID: 21838683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.
    Shahid M; Sobia F; Singh A; Malik A; Khan HM; Jonas D; Hawkey PM
    Crit Rev Microbiol; 2009; 35(2):81-108. PubMed ID: 19514910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
    Tooke CL; Hinchliffe P; Bragginton EC; Colenso CK; Hirvonen VHA; Takebayashi Y; Spencer J
    J Mol Biol; 2019 Aug; 431(18):3472-3500. PubMed ID: 30959050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactamases and beta-lactamase inhibitors.
    Williams JD
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 1():S3-7; discussion S26-7. PubMed ID: 10526867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [MULTIRESISTANT BACTERIA].
    Bedenić B; Sardelić S; Ladavac M
    Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.
    Livermore DM; Mushtaq S; Warner M; Miossec C; Woodford N
    J Antimicrob Chemother; 2008 Nov; 62(5):1053-6. PubMed ID: 18689875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
    Stock I
    Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors.
    Buynak JD
    Curr Med Chem; 2004 Jul; 11(14):1951-64. PubMed ID: 15279575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's new in antibiotic resistance? Focus on beta-lactamases.
    Babic M; Hujer AM; Bonomo RA
    Drug Resist Updat; 2006 Jun; 9(3):142-56. PubMed ID: 16899402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
    Papp-Wallace KM; Nguyen NQ; Jacobs MR; Bethel CR; Barnes MD; Kumar V; Bajaksouzian S; Rudin SD; Rather PN; Bhavsar S; Ravikumar T; Deshpande PK; Patil V; Yeole R; Bhagwat SS; Patel MV; van den Akker F; Bonomo RA
    J Med Chem; 2018 May; 61(9):4067-4086. PubMed ID: 29627985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.
    Livermore DM; Woodford N
    Trends Microbiol; 2006 Sep; 14(9):413-20. PubMed ID: 16876996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New promising β-lactamase inhibitors for clinical use.
    Olsen I
    Eur J Clin Microbiol Infect Dis; 2015 Jul; 34(7):1303-8. PubMed ID: 25864193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae.
    Bush K
    Curr Opin Microbiol; 2010 Oct; 13(5):558-64. PubMed ID: 20920882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal.
    Féria C; Ferreira E; Correia JD; Gonçalves J; Caniça M
    J Antimicrob Chemother; 2002 Jan; 49(1):77-85. PubMed ID: 11751770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Lactamases: A Focus on Current Challenges.
    Bonomo RA
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Actions and resistance mechanisms of beta-lactam antibiotics. Penicillin-binding proteins, beta-3-lactamases and signal proteins].
    Heisig P
    Pharm Unserer Zeit; 2006; 35(5):400-8. PubMed ID: 17009783
    [No Abstract]   [Full Text] [Related]  

  • 19. Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design.
    Wang JF; Chou KC
    Curr Top Med Chem; 2013; 13(10):1242-53. PubMed ID: 23647546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel beta-lactam antibiotics and inhibitor combinations.
    Bassetti M; Righi E; Viscoli C
    Expert Opin Investig Drugs; 2008 Mar; 17(3):285-96. PubMed ID: 18321228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.